TRxADE HEALTH, Inc.

As of March 26, 2025, TRxADE HEALTH, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a Price to Book Value of 0.12, negative ROCE and ROE, and significant underperformance compared to peers and the S&P 500.

As of June 4, 2025, the trend is mildly bearish, with mixed signals from key indicators suggesting weak bearish sentiment but some potential for recovery.

As of March 2022, the management team of TRxADE HEALTH, Inc. includes Mr. Surendra Ajjarapu (Chairman, CEO, Secretary), Mr. Prashant Patel (President, COO, Director), and Independent Directors Mr. Donald Fell, Mr. Michael Peterson, and Dr. Pamela Tenaerts. They oversee the company's strategic direction and operations.

TRxADE HEALTH, Inc. is an integrated pharmaceutical services company in the micro-cap market, currently reporting net sales of $0 million and a net loss of $3 million as of March 2025. The company has a market cap of $8.63 million and a dividend yield of 21.67%.

As of Jun 18, TRxADE HEALTH, Inc. has a market capitalization of 8.63 million and reported net sales of 0.14 million with a net profit of -14.66 million over the latest four quarters. Shareholder's funds are at 79.07 million and total assets at 107.38 million as of Dec 24.